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Accepted 11 December 2019; Published online 14 December 2019AbstractObjective: The objective of this study was to examine methodological and reporting characteristics of systematic reviews and meta-
analyses which compare diagnostic test accuracy (DTA) of multiple index tests, identify good practice, and develop guidance for better
reporting.
Study Design and Setting: Methodological survey of 127 comparative or multiple tests reviews published in 74 different general med-
ical and specialist journals. We summarized methods and reporting characteristics that are likely to differ between reviews of a single test
and comparative reviews. We then developed guidance to enhance reporting of test comparisons in DTA reviews.
Results: Of 127 reviews, 16 (13%) reviews restricted study selection and test comparisons to comparative accuracy studies while the
remaining 111 (87%) reviews included any study type. Fifty-three reviews (42%) statistically compared test accuracy with only 18 (34%) of
these using recommended methods. Reporting of several itemsdin particular the role of the index tests, test comparison strategy, and lim-
itations of indirect comparisons (i.e., comparisons involving any study type)dwas deficient in many reviews. Five reviews with exemplary
methods and reporting were identified.
Conclusion: Reporting quality of reviews which evaluate and compare multiple tests is poor. The guidance developed, complemented
with the exemplars, can assist review authors in producing better quality comparative reviews. Crown Copyright  2020 Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Comparative accuracy; Diagnostic accuracy; Test accuracy; Meta-analysis; Systematic review; Test comparison1. Introduction
Medical tests are essential in guiding patient manage-
ment decisions. Ideally, tests should only be recommended
for routine clinical use based on evidence of their clinical
performance (diagnostic accuracy) and clinical impact
(benefits and harms) derived from relevant, high-quality
primary studies, and systematic reviews. Systematic re-
views and meta-analyses of diagnostic test accuracy
(DTA) generally assess the performance of one index test
at a time, thus providing a limited view of the test options* Corresponding author. Institute of Applied Health Research, Univer-
sity of Birmingham, Birmingham B15 2TT, UK. Tel.: þ44 0121 4147833.
E-mail address: y.takwoingi@bham.ac.uk (Y. Takwoingi).
https://doi.org/10.1016/j.jclinepi.2019.12.007
0895-4356/Crown Copyright  2020 Published by Elsevier Inc. This is an open ac
licenses/by-nc-nd/4.0/).available for a given condition and no information about
the performance of alternatives. However, comparative re-
views which compare the accuracy of two or more index
tests are potentially more useful to clinicians and policy-
makers for guiding decision-making about optimal test
selection.
Because test evaluation is often limited to the assess-
ment of test accuracy with limited or no regulatory require-
ment to demonstrate clinical impact [1], it is vital that in the
rapidly expanding evidence base, comparative accuracy re-
views are conducted appropriately and well reported to
avoid misleading conclusions and recommendations.
Several reporting checklists have been developed to
improve the transparency and reproducibility of medical
research, including the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) checklistcess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 Methods known to have methodological flaws are
frequently used in reviews which evaluate and
compare the accuracy of multiple tests. Reporting
quality is variable but often poor.
 Test comparisons based on studies that have not
directly compared the index tests are common in
reviews but review authors fail to appreciate the
potential for bias due to confounding.
What this adds to what was known?
 Guidance developed to promote better conduct and
reporting of test comparisons in diagnostic accu-
racy reviews and to facilitate their appraisal. Ex-
emplars also provided to assist review authors.
What is the implication and what should change
now?
 To avoid misleading conclusions and recommenda-
tions, the methodological rigor and reporting of
comparative reviews should be improved.
 Researchers and funders should recognize the
merit of designing studies for obtaining reliable ev-
idence about the relative accuracy of competing
diagnostic tests.
[2] and PRISMA-DTA, the extension for DTA reviews [3].
Comparative accuracy reviews and meta-analyses are more
challenging to perform than those of a single test; high-
quality reporting will enable assessment of the credibility
of analysis methods and findings. Therefore, our aim was
to summarize the methodological and reporting characteris-
tics of comparative accuracy reviews, provide examples of
good practice, and develop guidance for improving the re-
porting of test comparisons in future DTA reviews.
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2.1. Terminology
To avoid confusion due to lack of standard terminology
for types of test accuracy studies and systematic reviews,
we describe here our choice of terminology. In Appendix
Box 1, we provide a summary and other relevant
definitions.
Unlike randomized controlled trials (RCTs) of interven-
tions, which have a control arm, most test accuracy studies
do not compare the index test with alternative index tests
[4]. We used the term ‘‘noncomparative’’ to describe a pri-
mary study that evaluated a single index test or only one ofthe index tests being evaluated in a review, and ‘‘compara-
tive’’ to describe a study that made a head-to-head compar-
ison by comparing the accuracy of at least two index tests
in the same study population. A comparative study may
either randomize patients to receive only one of the index
tests (randomized design), or apply all the index tests to
each patient (paired or within-subject design) [4]. With
both designs, patients also receive the reference standard.
For brevity, we will often refer to the index test simply as
test.
We defined a comparative accuracy review as a review
that met at least one of the following four criteria: (1) clear
objective to compare the accuracy of at least two tests; (2)
selected only comparative studies; (3) performed statistical
analyses comparing the accuracy of all or a pair of tests; or
(4) performed a direct (head-to-head) comparison of two
tests. Reviews that assessed multiple tests but did not meet
any of the four criteria were termed a multiple test review.
Such reviews assess each test individually without making
formal comparisons between tests and often include a large
number of tests such as signs and symptoms from clinical
examination. We included this category of reviews to be
comprehensive and to avoid excluding reviews in the
absence of established terminology.
The two main approaches for test comparisons in a DTA
review are direct and indirect (between-study uncontrolled)
comparisons (Appendix Fig. 1). In a direct comparison, on-
ly studies that have evaluated all the index tests are
included in the comparison, whereas an indirect compari-
son includes all eligible studies that have evaluated at least
one of the index tests.2.2. Data sources
We used an existing collection of 1,023 systematic re-
views published up to October 2012. The reviews were
originally identified for an earlier empirical study using a
previously described search strategy [4]. The reviews were
identified by searching the Database of Abstracts of Re-
views of Effects (DARE) for reviews with a structured ab-
stract and the Cochrane Database of Systematic Reviews
(CDSR issue 11, 2012). Reviews undergo quality appraisal
before inclusion in DARE and so we expect reviews in
DARE to be of higher quality than would be expected in
the wider literature. We did not update the search because
DARE is no longer being updated and we judged it unlikely
that more recent reviews from the general literature would
be of better methodological quality given the findings of
recent empiric studies of DTA reviews [5,6]. Early publica-
tions (1980s and 1990s) of DTA reviews followed method-
ology for intervention reviews and key advances in
methodology for DTA reviews were published between
1993 and 2005 [7]. For these reasons, and to make allow-
ance for dissemination of methods, reviews for the current
study were limited to a 5-year period from January 2008 to
October 2012.
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All test accuracy reviews that evaluated at least two tests
and included a meta-analysis were eligible. We excluded
reviews where full-text papers were unavailable, had insuf-
ficient data to determine study type (comparative or non-
comparative), or where different tests were analyzed
together as a single test without separate meta-analysis re-
sults for each test.
2.4. Review selection and data extraction
Using a revised screening form from a previous empiric
study, one assessor (Y.T. or C.P.) assessed review eligibility
by screening the abstract, followed by full-text examina-
tion. When eligibility was unclear, the inclusion decision
was made following discussion with a member of the
author team (J.D.).
We scrutinized full-text articles and their supplementary
files. Data extraction was undertaken by one assessor
(Y.T.). To verify the data, a random subset of half of the
included reviews was generated using the SURVEYSE-
LECT procedure in SAS software, version 9.2 (SAS Insti-
tute, Cary, NC, USA). Data were extracted from these
reviews by a second assessor. Any disagreements were dis-
cussed by the two assessors and agreement was achieved
without having to involve a third person. We focused on
methodological and reporting characteristics likely to differ
between reviews of a single test and comparative reviews.
We extracted data on general, methodological, and report-
ing characteristics. These included data on target condition,
tests evaluated, study design, and the analytical methods
used for comparing tests and investigating differences be-
tween studies.
2.5. Development of test comparison reporting
guidance
To identify a set of criteria, we used the list of method-
ological and reporting characteristics that we devised and
the PRISMA-DTA checklist, combined with theoretical
reasoning based on published methodological recommen-
dations [7e9] and the Cochrane Handbook for Systematic
Reviews of Diagnostic Test Accuracy [10]. The criteria
were selected to emphasize their importance for test com-
parisons when completing the PRISMA-DTA checklist
for a comparative review.
2.6. Data analysis
We computed descriptive statistics for categorical vari-
ables as frequencies and percentages. Continuous variables
were summarized using the median, range, and interquartile
range. Using the criteria and definition specified in section
2.1, we categorized reviews into comparative and multiple
tests reviews. We subdivided comparative reviews into
comparative reviews with and without a statisticalcomparison because one of the key aspects that we exam-
ined was synthesis methods. Thus we summarized and pre-
sented our findings within three review categories. All data
analyses were performed using Stata SE version 13.0 (Sta-
ta-Corp, College Station, TX, USA).3. Results
The flow of reviews through the screening and selection
process is shown in Fig. 1. Of the 1,023 reviews in the
collection, 127 reviews met the inclusion criteria.
3.1. General characteristics
There were 82 comparative reviews and 45 multiple test
reviews. Of the 82 comparative reviews, 53 (66%) formally
compared test accuracy. Characteristics of the 127 reviews
are summarized in Table 1. The reviews were published in
74 different journals, with the majority [93 (73%)] in
specialist medical journals. The reviews covered a broad
array of target conditions and test types, with neoplasms
(37%), and imaging tests (43%) being the most frequently
assessed target condition and test type. The median (inter-
quartile range) number of comparative and noncomparative
studies included per review were 6 (3 to 11) and 14 (3 to
24), respectively.
3.2. Statistical characteristics
3.2.1. Use of comparative studies and test comparison
strategies
Sixteen (13%) reviews restricted study selection and test
comparisons to comparative studies, whereas the remaining
111 (87%) reviews included any study type (Table 2). In 22
reviews (17%), both direct and indirect comparisons were
performed with the direct comparisons performed as sec-
ondary analyses using pairs of tests for which data were
available. Direct comparisons were not performed in 49
(39%) reviews even though comparative studies were avail-
able in 40 of the reviews and qualitative or quantitative syn-
theses would have been possible.
3.2.2. Methods for comparative meta-analysis and
informal comparisons
We classified methods used in the 53 comparative re-
views that statistically compared test accuracy into three
main groups: (1) na€ıve comparison (19/53, 36%) which re-
fers to a comparison where a statistical test, for example, a
Z-test, was used to compare summary estimates from sepa-
rate meta-analysis of one test with summary estimates from
the meta-analysis of another test; (2) univariate pooling of
differences in sensitivity and specificity, or pooling of dif-
ferences in the diagnostic odds ratio (6/53, 11%); and (3)
meta-regression by adding test type as a covariate to a
meta-analytic model (23/53, 44%). For the remaining 5
(9%) reviews, the method used was unclear. Relative
Fig. 1. Flow of reviews through the selection process. *The 82 comparative accuracy reviews met at least one of the following four criteria: (1) clear
objective to compare the accuracy of at least two tests; (2) selected only comparative studies; (3) performed statistical analyses comparing the
accuracy of all or at least a pair of tests; or (4) performed a direct (head-to-head) comparison of two tests.
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in 18 of the 53 (34%) reviews.
For the remaining 29 comparative reviews that did not
formally compare tests (i.e., through statistical quantifica-
tion of the difference in accuracy, either via a P-value or es-
timate of the difference), three (10%) determined the
statistical significance of differences in test accuracy based
on whether or not confidence intervals overlapped, nine
(31%) narratively compared tests, 14 (48%) did not
perform a comparison and three (10%) were unclear.3.2.3. Investigations of heterogeneity
Investigations of heterogeneity were performed for indi-
vidual tests in 67 (53%) reviews, of which 24 (36%) usedmeta-regression, 35 (52%) used subgroup analyses, and 8
(12%) used both methods (Table 3). Among the 53 compar-
ative reviews with a statistical comparison, 33 (62%) inves-
tigated heterogeneity. Five (15%) of the 33 reviews
assessed the effect of potential confounders on relative ac-
curacy using subgroup analyses (four reviews) or Bayesian
bivariate meta-regression (one review).3.3. Presentation and reporting
Thirteen reviews (10%) used a reporting guideline
(Table 4). Five reviews used PRISMA; four used
QUORUM (Quality of Reporting of Meta-analyses), the
precursor to PRISMA; one used both QUORUM and
Table 1. Descriptive characteristics of 127 reviews of comparative accuracy and multiple tests
Characteristic
Comparative reviews
Multiple test
reviews Total
Statistical test performed to compare
accuracy
Yes No or uncleara
Number of reviews 53 (42) 29 (23) 45 (35) 127
Year of publication
2008 14 (26) 11 (38) 13 (29) 38 (30)
2009 6 (11) 10 (34) 8 (18) 24 (19)
2010 16 (30) 4 (14) 11 (24) 31 (24)
2011 13 (25) 3 (10) 7 (16) 23 (18)
2012b 4 (8) 1 (3) 6 (13) 11 (9)
Type of publication
Cochrane review 3 (6) 1 (3) 1 (2) 5 (4)
General medical journal 5 (9) 5 (17) 13 (29) 23 (18)
Specialist medical journal 42 (79) 22 (76) 30 (64) 93 (73)
Technology assessment report 3 (6) 1 (3) 2 (4) 6 (5)
Number of tests evaluated
2 20 (38) 14 (48) 12 (27) 46 (36)
3 12 (23) 6 (21) 4 (9) 22 (17)
4 8 (15) 3 (10) 4 (9) 15 (12)
5 13 (25) 6 (21) 25 (56) 44 (35)
Clinical topic (according to ICD-11 Version: 2018)
Circulatory system 9 (17) 5 (17) 5 (11) 19 (15)
Digestive system 3 (6) 1 (3) 8 (18) 12 (9)
Infectious and parasitic diseases 3 (6) 4 (14) 9 (20) 16 (13)
Injury, poisoning, and certain other consequences
of external causes
2 (4) 1 (3) 2 (4) 5 (4)
Mental, behavioral, or neurodevelopmental disorders 2 (4) 1 (3) 3 (7) 6 (5)
Musculoskeletal system and connective tissue 1 (2) 1 (3) 4 (9) 6 (5)
Neoplasms 28 (53) 12 (41) 7 (16) 47 (37)
Other ICD-11 codesc 5 (9) 4 (14) 7 (16) 16 (13)
Type of tests evaluated
Biopsy 0 1 (3) 0 1 (1)
Clinical and physical examination 5 (9) 3 (10) 15 (33) 23 (18)
Device 1 (2) 0 0 1 (1)
Imaging 32 (60) 13 (45) 9 (20) 54 (43)
Laboratory 8 (15) 8 (28) 12 (27) 28 (22)
RDT or POCT 1 (2) 0 4 (9) 5 (4)
Self-administered questionnaire 1 (2) 1 (3) 0 2 (2)
Combinations of any of the aboved 5 (9) 3 (10) 5 (11) 13 (10)
Clinical purpose of the tests
Diagnostic 42 (79) 23 (79) 44 (98) 109 (86)
Monitoring 1 (2) 1 (3) 0 2 (2)
Prognostic/prediction 0 1 (3) 0 1 (1)
Response to treatment 1 (2) 0 0 1 (1)
Screening 3 (6) 4 (14) 1 (2) 8 (6)
Staging 6 (11) 0 0 6 (5)
Number of test accuracy studies in reviews
Median (range) 25 (6e103) 17 (5e82) 19 (3e79) 20 (3e103)
Interquartile range 14e43 11e32 12e24 12e34
Number of comparative studies
Median (range) 7 (0e59) 6 (0e32) 4 (0e52) 6 (0e59)
(Continued )
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Table 1. Continued
Characteristic
Comparative reviews
Multiple test
reviews Total
Statistical test performed to compare
accuracy
Yes No or uncleara
Interquartile range 4e14 1e11 2e10 3e11
Number of noncomparative studies
Median (range) 17 (0e98) 6 (0e79) 10 (0e76) 14 (0e98)
Interquartile range 6e32 0e27 5e20 3e24
Abbreviations: ICD-11, International Classification of Diseases, Eleventh Revision; RDT, rapid diagnostic test; POCT, point of care test.
Numbers in parentheses are column percentages unless otherwise stated. Percentages may not add up to 100% because of rounding.
a In 3 reviews, it was unclear whether a statistical comparison of test accuracy was done.
b Includes only studies published up to October 2012.
c Includes 8 ICD-11 codes that had fewer than 5 reviews across the 3 groups.
d Tests evaluated in a review were not of the same type.
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ing of Diagnostic accuracy), and MOOSE (Meta-analysis
of Observational Studies in Epidemiology); and the remain-
ing two stated they followed recommendations of the Co-
chrane DTA Working Group.
3.3.1. Summary of reporting quality and exemplars
Based on recommendations in the Cochrane Handbook
[12], five comparative reviews [13e17] were judged exem-
plary in terms of clarity of objectives and reporting of test
comparison methods. A brief summary of the reviews is
given in Appendix Table 1. Fig. 2 summarizes results for
10 reporting characteristics (derived from Table 4) for each
of the 127 reviews. The figure clearly shows that the report-
ing of several itemsdin particular the role of the index
tests, test comparison strategy and limitations of indirect
comparisonsdwas deficient in many reviews. Further de-
tails are provided in sections 3.3.2 to 3.3.6.
3.3.2. Review objectives and clinical pathway
A comparative objective was explicitly stated in 70
(55%) reviews (Table 4). It was possible to deduce the role
of the tests in 57 (45%) reviews as add on, triage, and/or
replacement for an existing test. For 28 of the 57 (49%) re-
views, the role was explicitly stated while we used implicit
information in the background and discussion sections to
make judgments for the remaining 29 (51%) reviews.
3.3.3. Study identification and characteristics
A flow diagram illustrating the selection of studies was
not presented in 41 (32%) reviews (Table 4). In 61 (48%)
reviews, a flow diagram was presented without the number
of studies per test, whereas 25 (20%) reviews presented a
comprehensive flow diagram with the number of studies
per test. Of these 25 reviews, the flow diagrams in five re-
views [14,18e21] were notable examples. These flow dia-
grams clearly showed the number of studies included in the
analysis of each test, and also indicated the number ofcomparative studies available. Of the 99 reviews that had
at least one comparative study, 50 (51%) reviews did not
identify the comparative studies. Most of the reviews
(92%) reported study characteristics; however, the detail re-
ported varied.
3.3.4. Strategy for comparing test accuracy
Seventy-three comparative reviews included both
comparative and noncomparative studies and 21 (29%) of
these reviews stated their strategy for comparing tests, that
is, direct and/or indirect comparisons (Table 4). Of the 21
reviews, 19 (90%) formally compared test accuracy.
3.3.5. Graphical presentation of test comparisons
An SROC plot showing results for two or more tests was
presented in 28 (22%) reviews, 47 (37%) reviews showed
each test on a separate SROC plot, and the remaining 52
(41%) reviews did not present an SROC plot (Table 4).
Two multiple test reviews and seven comparative reviews
without a formal test comparison presented an SROC plot
showing a test comparison.
3.3.6. Limitations of indirect comparisons
Twenty-one (17%) reviews restricted inclusion to
comparative studies (Table 4). Of the remaining 106 re-
views that included any study type, 18 (17%) acknowl-
edged the limitations of indirect comparisons.
Furthermore, 9 of these 18 reviews recommended that
future primary studies should directly compare the perfor-
mance of tests within the same patient population.4. Discussion
4.1. Principal findings
The findings of our methodological survey showed
considerable variation in methods and reporting. Despite
Table 2. Strategies and methods for test comparisons
Characteristic
Comparative reviews
Multiple test reviews Total
Statistical analyses to compare test
accuracy
Yes No or unclear
Number of reviewsa 53 (42) 29 (23) 45 (35) 127 (100)
Study type
Comparative only 8 (15) 8 (28) 0 16 (13)
Any study type 45 (85) 21 (72) 45 (100) 111 (87)
Test comparison strategy
Direct comparison only 8 (15) 8 (28) 0 16 (13)
Indirect comparison onlydcomparative
studies available
26 (49) 10 (34) 4 (9) 40 (32)
Indirect comparison onlydno
comparative studies available
2 (4) 6 (21) 1 (2) 9 (7)
Both direct and indirect comparison 17 (32) 5 (17) 0 22 (17)
None 0 0 40 (89) 40 (32)
Method used for test comparisonb
Meta-regressiondhierarchical model 18 (34) 0 0 18 (14)
Meta-regressiondSROC regression 2 (4) 0 0 2 (2)
Meta-regressiondANCOVA 2 (4) 0 0 2 (2)
Meta-regressiondlogistic regression 1 (2) 0 0 1 (1)
Univariate pooling of difference in
sensitivity and specificity or DORs
6 (11) 0 0 6 (5)
Na€ıve (comparison of pooled estimates
from separate meta-analyses)
0 0
Z-test 15 (28) 0 0 15 (12)
Paired t-test 1 (2) 0 0 1 (1)
Unpaired t-test 1 (2) 0 0 1 (1)
Chi-squared test 1 (2) 0 0 1 (1)
Comparison of Q* statistic and their
SEsc
1 (2) 0 0 1 (1)
Overlapping confidence intervals 0 3 (10) 0 3 (2)
Narrative 0 9 (31) 4 (9) 13 (10)
None 0 14 (48) 40 (89) 54 (43)
Unclear 5 (9) 3 (10) 1 (2) 9 (7)
Relative measures used to summarize
differences in test accuracy
18 (34) 0 0 18 (14)
Multiple thresholds included 13 (25) 12 (41) 17 (38) 42 (33)
If multiple thresholds included, were they
accounted for in the comparative
meta-analysis (meta-analysis at each
threshold or fitted appropriate model)
Yes 6 (46) 0 0 6 (46)
No 4 (31) 0 0 4 (31)
Unclear 3 (23) 0 0 3 (23)
Abbreviations: ANCOVA, analysis of covariance; DOR, diagnostic odds ratio; SE, standard error; SROC, summary receiver operating character-
istic.
Numbers in parentheses are column percentages unless otherwise stated. Percentages may not add up to 100% because of rounding.
a Numbers in parentheses are row percentages.
b These methods either involve a comparative meta-analysis or follow-on from a meta-analysis of each test individually.
c Moses et al. [11] proposed the Q* statistic as an alternative to the area under the curve. Q* is the point on the SROC curve where sensitivity is
equal to specificity, that is, the intersection of the summary curve and the line of symmetry.
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Table 3. Investigations of heterogeneity in comparative and multiple test reviews
Characteristic
Comparative reviews
Multiple test reviews Total
Statistical analyses to compare test
accuracy
Yes No or unclear
Number of reviewsa 53 (42) 29 (23) 45 (35) 127 (100)
Formal investigation performed
Yesdmeta-regression and subgroup
analyses
5 (9) 1 (3) 2 (4) 8 (6)
Yesdmeta-regression 15 (28) 5 (17) 4 (9) 24 (19)
Yesdsubgroup analyses 13 (25) 8 (28) 14 (31) 35 (28)
Nodlimited data 8 (15) 2 (7) 1 (2) 11 (9)
Nodonly tested for heterogeneity 3 (6) 8 (28) 16 (36) 27 (21)
Nodnothing reported 7 (13) 5 (17) 8 (18) 20 (16)
Unclear 2 (4) 0 0 2 (2)
If yes above, was effect on relative
accuracy also investigated?
Yes 5 (15) 0 0 5 (15)
No 21 (64) 0 0 21 (64)
Planned but no data 1 (3) 0 0 1 (3)
Unclear 6 (18) 0 0 6 (18)
Numbers in parentheses are column percentages unless otherwise stated. Percentages may not add up to 100% because of rounding.
a Numbers in parentheses are row percentages.
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poorly reported and the role of the tests was ambiguous
in many reviews. Comparative studies ensure validity by
comparing like with like, thus avoiding confounding but
only 16 reviews (13%) restricted study selection to compar-
ative studies. This may be due to scarcity of comparative
studies [4]. It is worth noting that only two tests were eval-
uated in most (81%) of the 16 reviews that restricted inclu-
sion to comparative studies.
The strategy adopted for test comparisons (direct com-
parisons and/or indirect comparisons) was not specified in
many reviews. Furthermore, the strategies that were speci-
fied varied considerably, reflecting a lack of understanding
of the best methods for comparative accuracy meta-
analysis. The validity of indirect comparisons largely de-
pends on assumptions about study characteristics but re-
views did not always report study characteristics. To pool
data for a direct or indirect comparison, the hierarchical
methods recommended for comparative meta-analysis were
not often used, with many reviews using methods known to
have methodological flaws that can lead to invalid statisti-
cal inference [12,22e24].
There are several potential sources of bias and variation
in test accuracy studies [25e27], and investigations of het-
erogeneity were commonly performed. However, the ana-
lyses were often performed separately for each test rather
than examining the effect jointly on all tests in a compari-
son. Understandably, the latter is rarely possible because of
limited data. As empirical findings have shown that results
of indirect comparisons are not always consistent withthose or direct comparisons [4], and adjusting for potential
confounders in an indirect comparison will be uncommon,
review findings should be carefully interpreted in the
context of the quality and the strength of the evidence.
Nevertheless, reviews seldom acknowledged the limitations
of indirect comparisons.4.2. Strengths and limitations
To our knowledge, a comprehensive overview of reviews
of comparative accuracy across different target conditions
and types of tests has not been undertaken. We thoroughly
examined a large sample of reviews published in a wide
range of journals. Our classification of reviews was inclu-
sive to enable a broad perspective of the literature and
the generalizability of our findings. In addition to docu-
menting review characteristics, we highlighted examples
of good practice that review authors can use as exemplars.
We also expanded relevant PRISMA-DTA items for report-
ing test comparisons in a DTA review.
Our study has limitations. First, the most recent review
in our cohort of reviews was published in October 2012.
Because the PRISMA-DTA checklist was published in
January 2018, we did not update the collection as there
had been no prior developments in reporting to suggest
more recently published reviews would be better reported
than older reviews. DARE is based on extensive searches
of a wide array of databases and also includes gray liter-
ature. Given that for a review to be included in DARE, it
must meet certain quality criteria, the quality of the
Table 4. Reporting and presentation characteristics of the reviews
Characteristic
Comparative reviews
Multiple test reviews Total
Statistical analyses to compare test
accuracy
Yes No or unclear
Number of reviewsa 53 (42) 29 (23) 45 (35) 127 (100)
Reporting guideline used 2 (4) 5 (17) 6 (13) 13 (10)
Clear comparative objective stated 45 (85) 25 (86) 0 70 (55)
Role of the tests
Add-on 6 (11) 3 (10) 2 (4) 11 (9)
Replacement 8 (15) 6 (21) 6 (13) 20 (16)
Triage 4 (8) 1 (3) 11 (24) 16 (13)
Any two of the above 4 (8) 4 (14) 2 (4) 10 (8)
Unclear 31 (58) 15 (52) 24 (53) 70 (55)
Flow diagram presented
Yesdincluded number of studies per
test
11 (21) 6 (21) 8 (18) 25 (20)
Yesdexcluded number of studies per
test
21 (40) 12 (41) 28 (62) 61 (48)
No 21 (40) 11 (38) 9 (20) 41 (32)
Comparative studies identified
Yes 31 (58) 9 (31) 9 (20) 49 (39)
No 16 (30) 7 (24) 27 (60) 50 (39)
No comparative studies in review 6 (11) 13 (45) 9 (20) 28 (22)
Study characteristics presented 48 (91) 26 (90) 43 (96) 117 (92)
Test comparison strategy
Yesb 19 (36) 2(7) 1 (2) 22 (17)
Nob 32 (60) 20 (69) 44 (98) 96 (76)
Nodincluded only comparative studies 2 (4) 7 (24) 0 9 (7)
Method used for test comparisonc
Yes 48 (91) NA NA 48 (91)
Unclear 5 (9) NA NA 5 (9)
2  2 data for each study 30 (57) 10 (34) 14 (31) 54 (43)
Individual study estimates of test
accuracy
46 (87) 25 (86) 36 (80) 107 (84)
Forest plot(s) 30 (57) 19 (66) 16 (36) 65 (51)
SROC plot
SROC plot comparing summary points
or curves for 2 or more tests
19 (36) 7 (26) 2 (4) 28 (22)
Separate SROC plot per test 17 (32) 11 (38) 19 (42) 47 (37)
No SROC plot 17 (32) 11 (38) 24 (53) 52 (41)
Limitations of indirect comparison
acknowledged
Yes 13 (25) 3 (10) 2 (4) 18 (14)
No 30 (57) 15 (52) 43 (96) 88 (69)
No but only comparative studies
included
10 (19) 11 (38) 0 21 (17)
Abbreviations: NA, not applicable; SROC, summary receiver operating characteristic.
Numbers in parentheses are column percentages unless otherwise stated. Percentages may not add up to 100% because of rounding.
a Numbers in parentheses are row percentages.
b These reviews included both comparative and noncomparative studies.
c These methods either involve a comparative meta-analysis or follow-on from a meta-analysis of each test individually.
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AB
C
Fig. 2. Reporting characteristics of 127 comparative and multiple test reviews. (A) Comparative reviews with statistical analyses performed
to compare accuracy; (B) Comparative reviews without statistical analyses to compare accuracy; (C) Multiple test reviews. The colored cells
in each row illustrate the reporting of the 10 items in each review. The box to the right of the figure gives the description of the reporting
items. Reviews were ordered by year of publication and the number of missing items within each of the three review categories A to C. All
multiple test reviews did not state a clear comparative objective (this was one of the four criteria used to classify the reviews as stated in
section 2.1).
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view is supported by a study of 100 DTA reviews pub-
lished between October 2017 and January 2018, which
found that the reviews were not fully informative when as-
sessed against the PRISMA-DTA and PRISMA-DTA for
abstracts reporting guidelines [6]. Furthermore, we exam-
ined the use of six comparative meta-analysis methods
that have been published since 2012 by checking their ci-
tations in Scopus [28e33]. Only one of the methods [31]
had been cited in a DTA review published in 2018. We
also conducted a search of MEDLINE (Ovid) on July
31, 2019, to identify DTA reviews published in 2019
(Appendix 1). Of 151 records retrieved, 43 reviews met
the inclusion criteria. The findings summarized in
Appendix 1 show that test comparison methods and re-
porting remain suboptimal. Thus, our collection of reviews
in this study reflects current practice.
Second, the assessment of the role of the tests was some-
times subjective and relied on the judgment of the assessor.
Therefore, we only considered whether the item was re-
ported or not, without assessing the quality of the descrip-
tion provided. We also discussed any uncertainty in a
judgment before making a final decision.4.3. Comparison with other studies
Previous research focused on systematic reviews of a
single test or overview of any review type without detailed
assessment of comparative reviews [6,34,35], specific clin-
ical area [36,37], or specific methodological issue [38e40].
Mallett et al. [36] and Cruciani et al. [37] concluded that
conduct and reporting of DTA reviews in cancer and infec-
tious diseases was poor. In an overview of DTA reviews
published between 1987 and 2009, 36% of reviews that
evaluated multiple tests reported statistical comparative an-
alyses [35]. Similarly, 42% of our reviews reported such
analyses.4.4. Guidance and implications for research and
practice
In Box 1, we provide reporting guidance for test com-
parisons to augment the PRISMA-DTA checklist and facil-
itate improvements in the reporting quality of comparative
reviews. The guidance can also be used by peer reviewers
and journal editors to appraise comparative DTA reviews.
The challenges of a DTA review and the added complexity
Box 1. Guidance for reporting test comparisons in systematic reviews of diagnostic accuracy
Item Description (PRISMA-DTA items)a Rationale and explanation
1 Role of tests in diagnostic pathway (3, D1) Test evaluation requires a clear objective and definition of the intended use
and role of a test within the context of a clinical pathway for a specific
population with the target condition. The intended role of a test guides
formulation of the review question and provides a framework for
assessing test accuracy, including the choice of a comparator(s) and
selection of studies. The role of a test is therefore important for
understanding the context in which the tests will be used and the
interpretation of the meta-analytic findings. The existing diagnostic
pathway and the current or proposed role of the index test(s) in the
pathway should be described. A new test may replace an existing one
(replacement), be used before the existing test (triage) or after the
existing test (add-on) [9].
2 Test comparison strategy [13] Comparative studies are ideal but they are scarce [4]. An indirect
between-study (uncontrolled) test comparison uses a different set of
studies for each test and so does not ensure like-with-like
comparisons; the difference in accuracy is prone to confounding
because of differences in patient groups and study methods.
Although direct comparisons based on only comparative studies are
likely to ensure an unbiased comparison and enhance validity, such
analyses may not always be feasible because of limited availability of
comparative studies. Conversely, an indirect comparison uses all
eligible studies that have evaluated at least one of the tests of interest
thus maximizing use of the available data (see Appendix Fig. 1). If
study selection is not limited to comparative studies and
comparative studies are available, a direct comparison should be
considered in addition to an indirect comparison. The direct
comparison may be narrative or quantitative depending on the
availability of comparative studies.
3 Meta-analytic methods (D2) Hierarchical models which account for between-study correlation in
sensitivity and specificity while also allowing for variability within and
between studies are recommended for meta-analysis of test accuracy
studies [8,12]. The two main hierarchical models are the bivariate and
the hierarchical summary receiver operating characteristic (HSROC)
models which focus on the estimation of summary points (summary
sensitivities and specificities) and SROC curves, respectively (see
Appendix Fig. 2) [41,42]. For the summary point of a test to have a
clinically meaningful interpretation, the analysis should be based on
data at a given threshold. For the estimation of an SROC curve, data
from all studies, regardless of threshold, can be included. As such,
test comparisons may be based on a comparison of summary points
and/or SROC curves. For the estimation of an SROC curve using the
HSROC model, one threshold per study is selected for inclusion in
the analysis. If multiple cutoffs were considered, the description of
methods should include how the cutoffs were selected and handled
in the analyses. Methods have been proposed which allow inclusion
of data from multiple thresholds for each study but the methods are
yet to be applied to test comparisons.
4 Identification of included studies for each
test [16]
Review complexity increases with increasing number of tests, target
conditions, uses and/or target populations within a single review.
Therefore, distinguishing between the different groups of studies that
contribute to different analyses in the review enhances clarity. The
PRISMA flow diagram can be extended to show the number of included
studies for each test or group of tests if inclusion is not limited to
comparative studies. The detail showndindividual tests or groups of
tests, settings and populationsdwill depend on the volume of information
and the ability of the review team to neatly summarize the information. If
such a comprehensive flow diagram is not feasible, the studies
contributing to the assessment of each test can be clearly identified in the
manuscript in some other way. The source of the evidence should be
declared by stating types of included studies. Studies contributing direct
evidence should also be clearly identified in the review.
(Continued )
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Box 1. Continued
Item Description (PRISMA-DTA items)a Rationale and explanation
5 Study characteristics [17] Relevant characteristics for each included study should be provided. This
may be summarized in a table and should include elements of study
design if eligibility was not restricted to specific design features.
Heterogeneity is often observed in test accuracy reviews and differences
between tests may be confounded by differences in study characteristics.
Confounders can potentially be adjusted for in indirect test comparisons,
though this is likely to be unachievable due to small number of studies
and/or incomplete information on confounders. The effect of factors that
may explain variation in test performance is typically assessed separately
for each test.
6 Study estimates of test performance and
graphical summaries e.g., forest plot and/
or SROC plot [19]
It is desirable to report 2  2 data (number of true positives, false positives,
false negatives, and true negatives) and summary statistics of test
performance from each included study. This may be done graphically
(e.g., forest plots) or in tables. Such summaries of the data will inform the
reader about the degree to which study-specific estimates deviate from
the overall summaries, as well as the size and precision of each study. It
is plausible that study results for one test may be more consistent or
precise than those of another test in an indirect comparison. In addition to
forest plots, reviews may include SROC plots such as those shown in
Appendix Figures 1 and 2. An SROC plot of sensitivity against
specificity displays the results of the included studies as points in
ROC space. The plot can also showmeta-analytic summaries such as
SROC curves (panel B in Appendix Fig. 2) or summary points
(summary sensitivities and specificities) with corresponding
confidence and/or prediction regions to illustrate uncertainty and
heterogeneity, respectively (panel A in Appendix Fig. 2). Ideally,
results from a test comparison should be shown on a single SROC
plot instead of showing the results for each test on a separate SROC
plot. Furthermore, for pairwise direct comparisons, the pair of points
representing the results of the two tests from each study can be
identified on the plot by adding a connecting line between the points
such as in the plot shown in panel B of Appendix Fig. 1.
7 Limitations of the evidence from indirect
comparisons [23,24]
This is only applicable for reviews that include indirect comparisons. Be
clear about the quality and strength of the evidence when interpreting the
results, including limitations of including noncomparative studies in a test
comparison. The results of indirect comparisons should be carefully
interpreted taking into account the possibility that differences in test
performance may be confounded by clinical and/or methodological
factors. This is essential because it is seldom feasible to assess the effect
of potential confounders on relative accuracy.
a Related to the PRISMA-DTA item(s) indicated in parentheses.
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ing because of their increasing role in health technology
assessment and clinical guideline development. Space con-
straints in journals are not an excuse for poor reporting
because many journals publish online supplementary files.
We noted that 56 (44%) reviews used supplementary files
to provide additional data and information. Tutorial guides
should be developed to assist review authors in navigating
and understanding the complexity of DTA review methods.
The Cochrane Screening and Diagnostic Tests Methods
Group have already made contributions by providing freely
available distance learning materials and tutorials on their
website.
Because long-term RCTs of test-plus-treatment strate-
gies which evaluate the benefits of a new test relative to
current best practice are not always feasible [43,44] andare rare [45], comparative accuracy reviews are an impor-
tant surrogate for guiding test selection and decision-
making. However, given the preponderance of indirect
comparisons and paucity of comparative studies, there is
a need to educate trialists, clinical investigators, funders,
and ethics committees about the merit of comparative
studies for obtaining reliable evidence about the relative
performance of competing diagnostic tests.5. Conclusions
Comparative accuracy reviews can inform decisions
about test selection but suboptimal conduct and reporting
will compromise their validity and relevance. Complete
and unambiguous reporting is therefore needed to enhance
13Y. Takwoingi et al. / Journal of Clinical Epidemiology 121 (2020) 1e14their use and minimize research waste. We advocate using
the guidance we have provided as an adjunct to the
PRISMA-DTA checklist to promote better conduct and re-
porting of test comparisons in DTA reviews.CRediT authorship contribution statement
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